Steris (STE) Cash & Equivalents (2017 - 2026)

Steris has reported Cash & Equivalents for 9 years, with the latest figure at $423.7 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents rose 173.04% year-over-year to $423.7 million; the trailing twelve-month figure through Dec 2025 stood at $423.7 million (up 173.04% YoY), and the FY2025 full-year result was $171.7 million, down 17.06% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $423.7 million, up from $319.2 million in the prior quarter.
• The five-year high for Cash & Equivalents was $534.8 million in Q2 2021, with the low at $155.2 million in Q4 2024.
• Average Cash & Equivalents over 5 years is $271.7 million, with a median of $239.4 million recorded in 2021.
• Year-over-year, Cash & Equivalents plunged 40.85% in 2022 and jumped 173.04% in 2025.
• Tracing STE's Cash & Equivalents over 5 years: stood at $359.1 million in 2021, then declined by 27.77% to $259.4 million in 2022, then declined by 24.59% to $195.6 million in 2023, then declined by 20.66% to $155.2 million in 2024, then soared by 173.04% to $423.7 million in 2025.
• The last three Cash & Equivalents figures came in at $423.7 million (Q4 2025), $319.2 million (Q3 2025), and $279.7 million (Q2 2025), per Business Quant data.

Peer Comparison